This review proposes that GLP-1 — the same peptide targeted by weight loss drugs — may contribute to IBS symptoms by acting as a signal transducer in the gut-brain axis, and that GLP-1 mimetics have shown early promise for IBS pain relief.
GLP-1 mimetic reduced IBS painA GLP-1 receptor agonist was found to alleviate acute pain symptoms in IBS patients — early clinical evidence for this peptide's role in the condition
What the researchers found
L-cells in the gastrointestinal epithelium secrete GLP-1 in response to luminal factors — including short-chain fatty acids, bile acids, and microbial metabolites — that are specifically altered in IBS patients. GLP-1 can act as a hormone, paracrine factor, or neuromodulator, interacting with the HPA stress axis, immune system, and gut neurons, all of which are dysregulated in IBS.
A GLP-1 mimetic has been found to alleviate acute pain symptoms in IBS patients, providing early clinical evidence that GLP-1 signaling may be important in IBS symptom manifestation. The review proposes that GLP-1 and L-cells function as signal transducers in the microbiome-gut-brain axis.
Why it matters
With millions of people now taking GLP-1 drugs for weight loss and diabetes, understanding GLP-1's effects on gut function is increasingly important. This review suggests these drugs may have unrecognized effects — positive or negative — on IBS symptoms. It also opens a new therapeutic avenue for IBS, a condition with limited effective treatments, by targeting a well-characterized peptide pathway.
How the study worked
This is a narrative review published in Experimental Physiology that synthesizes evidence from basic science, neuroendocrinology, and clinical observations to build the case for GLP-1's involvement in IBS pathophysiology. It examines L-cell biology, GLP-1 signaling pathways, and their intersection with known IBS pathophysiological mechanisms.
What this study cannot tell us
As a review, no new experimental data is presented. The evidence linking GLP-1 to IBS is largely mechanistic and inferential — the clinical evidence is limited to one mention of a GLP-1 mimetic reducing IBS pain. The heterogeneity of IBS (different subtypes, triggers, and mechanisms) makes it difficult to assign a single peptide a central role. The review focuses on GLP-1 but IBS involves many other peptides and signaling molecules.
How to read the evidence
This is a narrative review synthesizing mechanistic and limited clinical evidence. While the biological rationale is well-constructed, the direct clinical evidence for GLP-1's role in IBS is preliminary. Evidence strength is low to moderate.
When this study was published
Published in 2019, this review predates the widespread clinical use of semaglutide and tirzepatide for weight loss. Since then, real-world experience with millions of GLP-1 drug users has generated new observations about GI effects that make this review more relevant than ever.
The bigger picture
This review bridges two major research areas: the GLP-1 revolution in metabolic medicine and the growing understanding of the gut-brain axis in functional bowel disorders. As GLP-1 drugs become some of the most prescribed medications in the world, their effects on gut motility, visceral pain, and the microbiome are gaining urgency. Anecdotal reports from GLP-1 drug users about changes in bowel habits align with the mechanisms described here.
Questions still open
- Do patients taking GLP-1 drugs for weight loss experience changes in IBS symptoms, and if so, improvement or worsening?
- Could GLP-1 receptor agonists be repurposed specifically for IBS treatment, particularly for visceral pain?
- How do changes in the gut microbiome in IBS alter L-cell GLP-1 secretion patterns?
Common questions
Could GLP-1 drugs like Ozempic help or hurt IBS symptoms?
What are L-cells and why do they matter for IBS?
Read the original research
Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.
Experimental physiology, 104(1), 3-10
Citation
O'Malley, Dervla. (2019). Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.. Experimental physiology, 104(1), 3-10. https://doi.org/10.1113/EP087443